Contact the Editorial Desk

Editorial correspondence

NXT LVL Peptides tracks corrections and updates on CJC-1295, CJC-1295 / Ipamorelin, and tesamorelin: a citation stated inaccurately, a newly published trial, a regulatory status change, or a source that should appear on the references page. This is the most useful class of message this desk receives.

The most actionable submissions name the page, the exact passage in question, and a supporting source — a DOI or PubMed identifier where possible. That format lets a proposed change be checked against its source before anything is edited.

Editorial mailbox: editors@nxtlvlpeptides.com

What this desk cannot do

NXT LVL Peptides is a literature digest, not a clinical service or a vendor. It cannot advise on human use of any compound discussed here, recommend a dose or schedule, evaluate whether a cited trial applies to a specific person, or help locate, source, or purchase any compound from any supplier.

Tesamorelin is a prescription medicine available only through a licensed provider, for its approved indication. CJC-1295 and CJC-1295 / Ipamorelin are unapproved research chemicals; this desk does not advise on their acquisition or use. Readers subject to anti-doping rules should note that all three compounds fall under WADA's peptide-hormone restrictions. Editorial responses are not guaranteed and may be delayed.